BioMarin Pharma (BMRN) Tops Q1 EPS by 32c, Offers Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/13/2026

1. CSCO
2. CBRS
3. COHR
4. SPY
5. STUB
6. EAT
7. BTGO
8. NVDA
9. WYFI
10. ARX

April 28, 2016 4:24 PM EDT

BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of ($0.53), $0.32 better than the analyst estimate of ($0.85). Revenue for the quarter came in at $236.7 million versus the consensus estimate of $240.21 million.

2016 Financial Guidance

Revenue Guidance ($ in millions)

Item
ProvidedFebruary 25, 2016 Updated April 28, 2016
Total BioMarin Revenues $1,050 to $1,100 Unchanged
Vimizim Net Product Revenue $300 to $330 $315 to $340
Naglazyme Net Product Revenue $290 to $320 Unchanged
Kuvan Net Product Revenue $320 to $350 Unchanged

Select Income Statement Guidance ($ in millions, except percentages)

Item
ProvidedFebruary 25, 2016 Updated April 28, 2016
Cost of Sales (% of Total Revenue) 18.0% to 19.0% Unchanged
Selling, General and Admin. Expense $470 to $490 Unchanged
Research and Development Expense $680 to $720 Unchanged
Non - GAAP Net Loss $(75) to $(100) Unchanged
GAAP Net Loss $(400) to $(430) $(355) to $(385)*

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings